28 -> 2. Andrianov V, Gailite V, Lola D, et al (2009), "Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR", *European journal of medicinal chemistry*, 44(3), pp.1067-1085.
15 -> 3. Bergman JA, Woan K, Perez-Villarroel P, et al (2012), "Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth", *Journal of medicinal chemistry*, 55(22), pp.9891-9899.
8 -> 4. Bertrand P (2010), "Inside HDAC with HDAC inhibitors", *European journal of medicinal chemistry*, 45(6), pp.2095-2116.
29 -> 5. Bozorgi AH, Bagheri M, Aslebagh R, et al (2013), "A structure-activity relationship survey of histone deacetylase (HDAC) inhibitors", *Chemometrics and Intelligent Laboratory Systems*, 125, pp.132-138.
3 -> 6. Chen PC, Patil V, Guerrant W, et al (2008), "Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group", *Bioorganic \& medicinal chemistry*, 16(9), pp.4839-4853.
14 -> 7. Damaskos C, Valsami S, Kontos M, et al (2017), "Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer", *Anticancer Research*, 37(1), pp.35-46.
10 -> 8. de Ruijter AJ, van Gennip AH, Caron HN, et al (2003), "Histone deacetylases (HDACs): characterization of the classical HDAC family", *Biochemical Journal*, 370(3), pp.737-749.
26 -> 9. Di Micco S, Chini MG, Terracciano S, et al (2013), "Structural basis for the design and synthesis of selective HDAC inhibitors", *Bioorganic \& medicinal chemistry*, 21(13), pp.3795-3807.
9 -> 10. Dokmanovic M, Marks PA (2005), "Prospects: Histone deacetylase inhibitors", *Journal of cellular biochemistry*, 96(2), pp.293-304.
35 -> 11. Dung do TM, Dung PT, Oanh DT, et al (2015), "Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents", *Medicinal Chemistry*, 11(8), pp.725-735.
33 -> 12. Feng T, Wang H, Su H, et al (2013), "Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2)", *Bioorganic \& medicinal chemistry*, 21(17), pp.5339-5354.
1 -> 13. Giannini G, Cabri W, Fattorusso C, et al (2012), "Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives", *Future medicinal chemistry*, 4(11), pp.1439-1460.
12 -> 14. Glozak MA, Seto E (2007), "Histone deacetylases and cancer", *Oncogene*, 26(37), pp.5420-5432.
27 -> 15. Gołąbek K, Strzelczyk JK, Wiczkowski A, et al (2015), "Potential use of histone deacetylase inhibitors in cancer therapy", *Contemp Oncol (Pozn)*, 19(6), pp.436-440.
37 -> 16. Hanessian S, Auzzas L, Giannini G, et al (2007), "$\omega$-Alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: A study of chain-length and stereochemical dependence", *Bioorganic \& medicinal chemistry letters*, 17(22), pp.6261-6265.
44 -> 17. Hein JE, Fokin VV (2010), "Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper (I) acetylides", *Chemical Society Reviews*, 39(4), pp.1302-1315.
11 -> 18. Johnstone RW (2002), "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", *Nature reviews Drug discovery*, 1(4), pp.287-299.
21 -> 19. Jones P, Altamura S, Chakravarty PK, et al (2006), "A series of novel, potent, and selective histone deacetylase inhibitors", *Bioorganic \& Medicinal Chemistry Letters*, 16(23), pp.5948-5952.
22 -> 20. Jones P, Altamura S, Chakravarty PK, et al (2007), "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", *Blood*, 109(1), pp.31-39.
23 -> 21. Jones P, Altamura S, Chakravarty PK, et al (2014), "Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders", *Nature reviews Drug discovery*, 13(9), pp.673-691.
25 -> 22. Juvale DC, Kulkarni VV, Deokar HS, et al (2006), "3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues", *Organic \& biomolecular chemistry*, 4(15), pp.2858-2868.
2 -> 23. Kim HJ, Bae SC (2011), "Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs", *Am J Transl Res*, 3(2), pp.166-179.
40 -> 24. Kolb HC, Finn MG, Sharpless KB (2001), "Click Chemistry: Diverse Chemical Function from a Few Good Reactions", *Angewandte Chemie International Edition*, 40(11), pp.2004-2021.
39 -> 25. Kolb HC, Sharpless KB (2003), "The growing impact of click chemistry on drug discovery", *Drug discovery today*, 8(24), pp.1128-1137.
30 -> 26. Kozikowski AP, Chen Y, Gaysin AM, et al (2008), "Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC InhibitorsNanomolar-Potency Inhibitors of Pancreatic Cancer Cell Growth", *ChemMedChem*, 3(3), pp.487-501.
36 -> 27. Lee JH, Mahendran A, Yao Y, et al (2013), "Development of a histone deacetylase 6 inhibitor and its biological effects", *Proceedings of the National Academy of Sciences*, 110(39), pp.15704-15709.
43 -> 28. Lipshutz BH, Taft BR (2006), "Heterogeneous Copper-in-Charcoal-Catalyzed Click Chemistry", *Angewandte Chemie*, 118(48), pp.8415-8418.
13 -> 29. Mottamal M, Zheng S, Huang TL, et al (2015), "Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents", *Molecules*, 20(3), pp.3898-3941.
4 -> 30. Nam NH, Huong TL, Dung do TM, et al (2013), "Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *European journal of medicinal chemistry*, 70, pp.477-486.
6 -> 31. Nam NH, Huong TL, Dung do TM, et al (2014), "Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *Journal of enzyme inhibition and medicinal chemistry*, 29(5), pp.611-618.
7 -> 32. Oanh DT, Hai HV, Park SH, et al (2011), "Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *Bioorganic \& medicinal chemistry letters*, 21(24), pp.7509-7512.
32 -> 33. Ragno R, Simeoni S, Rotili D, et al (2008), "Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies", *European journal of medicinal chemistry*, 43(3), pp.621-632.
19 -> 34. Rasheed WK, Johnstone RW, Prince HM (2007), "Histone deacetylase inhibitors in cancer therapy", *Expert opinion on investigational drugs*, 16(5), pp.659-678.
41 -> 35. Rostovtsev VV, Green LG, Fokin VV, et al (2002), "A stepwise huisgen cycloaddition process: copper (I)-catalyzed regioselective ligation of azides and terminal alkynes", *Angewandte Chemie*, 114(14), pp.2708-2711.
16 -> 36. Somoza JR, Skene RJ, Katz BA, et al (2004), "Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases", *Structure*, 12(7), pp.1325-1334.
24 -> 37. Thangapandian S, John S, Sakkiah S, et al (2010), "Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery", *Journal of Molecular Graphics and Modelling*, 29(3), pp.382-395.
42 -> 38. Tornøe CW, Christensen C, Meldal M (2002), "Peptidotriazoles on solid phase:[1, 2, 3]-triazoles by regiospecific copper (I)-catalyzed 1, 3-dipolar cycloadditions of terminal alkynes to azides", *The Journal of organic chemistry*, 67(9), pp.3057-3064.
17 -> 39. Vannini A, Volpari C, Filocamo G, et al (2004), "Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor", *Proceedings of the National Academy of Sciences of the United States of America*, 101(42), pp.15064-15069.
31 -> 40. Wang DF, Wiest O, Helquist P, et al (2004), "QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids", *Bioorganic \& medicinal chemistry letters*, 14(3), pp.707-711.
20 -> 41. West AC, Johnstone RW (2014), "New and emerging HDAC inhibitors for cancer treatment", *The Journal of clinical investigation*, 124(1), pp.30-39.
34 -> 42. Zhang Z, Hou S, Chen H, et al (2016), "Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors", *Bioorganic \& medicinal chemistry letters*, 26(12), pp.2931-2935.
2. Andrianov V, Gailite V, Lola D, et al (2009), "Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR", *European journal of medicinal chemistry*, 44(3), pp.1067-1085.
3. Bergman JA, Woan K, Perez-Villarroel P, et al (2012), "Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth", *Journal of medicinal chemistry*, 55(22), pp.9891-9899.
4. Bertrand P (2010), "Inside HDAC with HDAC inhibitors", *European journal of medicinal chemistry*, 45(6), pp.2095-2116.
5. Bozorgi AH, Bagheri M, Aslebagh R, et al (2013), "A structure-activity relationship survey of histone deacetylase (HDAC) inhibitors", *Chemometrics and Intelligent Laboratory Systems*, 125, pp.132-138.
6. Chen PC, Patil V, Guerrant W, et al (2008), "Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group", *Bioorganic \& medicinal chemistry*, 16(9), pp.4839-4853.
7. Damaskos C, Valsami S, Kontos M, et al (2017), "Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer", *Anticancer Research*, 37(1), pp.35-46.
8. de Ruijter AJ, van Gennip AH, Caron HN, et al (2003), "Histone deacetylases (HDACs): characterization of the classical HDAC family", *Biochemical Journal*, 370(3), pp.737-749.
9. Di Micco S, Chini MG, Terracciano S, et al (2013), "Structural basis for the design and synthesis of selective HDAC inhibitors", *Bioorganic \& medicinal chemistry*, 21(13), pp.3795-3807.
10. Dokmanovic M, Marks PA (2005), "Prospects: Histone deacetylase inhibitors", *Journal of cellular biochemistry*, 96(2), pp.293-304.
11. Dung do TM, Dung PT, Oanh DT, et al (2015), "Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents", *Medicinal Chemistry*, 11(8), pp.725-735.
12. Feng T, Wang H, Su H, et al (2013), "Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2)", *Bioorganic \& medicinal chemistry*, 21(17), pp.5339-5354.
13. Giannini G, Cabri W, Fattorusso C, et al (2012), "Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives", *Future medicinal chemistry*, 4(11), pp.1439-1460.
14. Glozak MA, Seto E (2007), "Histone deacetylases and cancer", *Oncogene*, 26(37), pp.5420-5432.
15. Gołąbek K, Strzelczyk JK, Wiczkowski A, et al (2015), "Potential use of histone deacetylase inhibitors in cancer therapy", *Contemp Oncol (Pozn)*, 19(6), pp.436-440.
16. Hanessian S, Auzzas L, Giannini G, et al (2007), "$\omega$-Alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: A study of chain-length and stereochemical dependence", *Bioorganic \& medicinal chemistry letters*, 17(22), pp.6261-6265.
17. Hein JE, Fokin VV (2010), "Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper (I) acetylides", *Chemical Society Reviews*, 39(4), pp.1302-1315.
18. Johnstone RW (2002), "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", *Nature reviews Drug discovery*, 1(4), pp.287-299.
19. Jones P, Altamura S, Chakravarty PK, et al (2006), "A series of novel, potent, and selective histone deacetylase inhibitors", *Bioorganic \& Medicinal Chemistry Letters*, 16(23), pp.5948-5952.
20. Jones P, Altamura S, Chakravarty PK, et al (2007), "Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)", *Blood*, 109(1), pp.31-39.
21. Jones P, Altamura S, Chakravarty PK, et al (2014), "Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders", *Nature reviews Drug discovery*, 13(9), pp.673-691.
22. Juvale DC, Kulkarni VV, Deokar HS, et al (2006), "3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues", *Organic \& biomolecular chemistry*, 4(15), pp.2858-2868.
23. Kim HJ, Bae SC (2011), "Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs", *Am J Transl Res*, 3(2), pp.166-179.
24. Kolb HC, Finn MG, Sharpless KB (2001), "Click Chemistry: Diverse Chemical Function from a Few Good Reactions", *Angewandte Chemie International Edition*, 40(11), pp.2004-2021.
25. Kolb HC, Sharpless KB (2003), "The growing impact of click chemistry on drug discovery", *Drug discovery today*, 8(24), pp.1128-1137.
26. Kozikowski AP, Chen Y, Gaysin AM, et al (2008), "Chemistry, Biology, and QSAR Studies of Substituted Biaryl Hydroxamates and Mercaptoacetamides as HDAC InhibitorsNanomolar-Potency Inhibitors of Pancreatic Cancer Cell Growth", *ChemMedChem*, 3(3), pp.487-501.
27. Lee JH, Mahendran A, Yao Y, et al (2013), "Development of a histone deacetylase 6 inhibitor and its biological effects", *Proceedings of the National Academy of Sciences*, 110(39), pp.15704-15709.
28. Lipshutz BH, Taft BR (2006), "Heterogeneous Copper-in-Charcoal-Catalyzed Click Chemistry", *Angewandte Chemie*, 118(48), pp.8415-8418.
29. Mottamal M, Zheng S, Huang TL, et al (2015), "Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents", *Molecules*, 20(3), pp.3898-3941.
30. Nam NH, Huong TL, Dung do TM, et al (2013), "Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *European journal of medicinal chemistry*, 70, pp.477-486.
31. Nam NH, Huong TL, Dung do TM, et al (2014), "Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *Journal of enzyme inhibition and medicinal chemistry*, 29(5), pp.611-618.
32. Oanh DT, Hai HV, Park SH, et al (2011), "Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents", *Bioorganic \& medicinal chemistry letters*, 21(24), pp.7509-7512.
33. Ragno R, Simeoni S, Rotili D, et al (2008), "Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies", *European journal of medicinal chemistry*, 43(3), pp.621-632.
34. Rasheed WK, Johnstone RW, Prince HM (2007), "Histone deacetylase inhibitors in cancer therapy", *Expert opinion on investigational drugs*, 16(5), pp.659-678.
35. Rostovtsev VV, Green LG, Fokin VV, et al (2002), "A stepwise huisgen cycloaddition process: copper (I)-catalyzed regioselective ligation of azides and terminal alkynes", *Angewandte Chemie*, 114(14), pp.2708-2711.
36. Somoza JR, Skene RJ, Katz BA, et al (2004), "Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases", *Structure*, 12(7), pp.1325-1334.
37. Thangapandian S, John S, Sakkiah S, et al (2010), "Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery", *Journal of Molecular Graphics and Modelling*, 29(3), pp.382-395.
38. Tornøe CW, Christensen C, Meldal M (2002), "Peptidotriazoles on solid phase:[1, 2, 3]-triazoles by regiospecific copper (I)-catalyzed 1, 3-dipolar cycloadditions of terminal alkynes to azides", *The Journal of organic chemistry*, 67(9), pp.3057-3064.
39. Vannini A, Volpari C, Filocamo G, et al (2004), "Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor", *Proceedings of the National Academy of Sciences of the United States of America*, 101(42), pp.15064-15069.
40. Wang DF, Wiest O, Helquist P, et al (2004), "QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids", *Bioorganic \& medicinal chemistry letters*, 14(3), pp.707-711.
41. West AC, Johnstone RW (2014), "New and emerging HDAC inhibitors for cancer treatment", *The Journal of clinical investigation*, 124(1), pp.30-39.
42. Zhang Z, Hou S, Chen H, et al (2016), "Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors", *Bioorganic \& medicinal chemistry letters*, 26(12), pp.2931-2935.
